Denali Therapeutics Inc.
COMPOUNDS, COMPOSITIONS, AND METHODS
Last updated:
Abstract:
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
Status:
Application
Type:
Utility
Filling date:
13 Mar 2020
Issue date:
7 Jan 2021